RCS - Ergomed plc - Ergomed’s PrimeVigilance Supports COVID-19 Trial

ErgomedAnnouncement

30/03/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200330:nRSd9601Ha

RNS Number : 9601H  Ergomed plc  30 March 2020

RNS REACH

PRESS RELEASE

 

 

Ergomed's PrimeVigilance Announces Provision of Clinical Safety Services for
COVID-19 Clinical Trial Program

Guildford, UK - 30 March 2020: Ergomed plc (LSE: ERGO) ('Ergomed' or the
'Company'), a company focused on providing specialised services to the
pharmaceutical industry, today announces that it will provide drug safety
services through its specialist pharmacovigilance provider, PrimeVigilance,
for an ongoing US clinical trial to assess the effect of a rheumatoid
arthritis treatment on patients with severe COVID-19 infection.

Dr Miroslav Reljanović, Executive Chairman of Ergomed, said: "COVID-19
represents a severe and pressing challenge for all involved in the development
of new medicines and we are proud to be expanding our involvement in the field
by bringing our expertise in drug safety and pharmacovigilance to this
program. The rapid initiation of clinical trials and establishment of
appropriate safety monitoring will be critical to providing new treatments
which may improve outcomes for patients."

ENDS

 

Enquiries:

 

 Ergomed plc                                             Tel: +44 (0) 1483 402 975
 Miroslav Reljanović (Executive Chairman)
 Richard Barfield (Chief Financial Officer)

 Numis Securities Limited                               Tel: +44 (0) 20 7260 1000
 Freddie Barnfield / Huw Jeremy (Nominated Adviser)
 James Black (Broker)

 Consilium Strategic Communications - for UK enquiries  Tel: +44 (0) 20 3709 5700
 Chris Gardner / Sue Stuart                             ergomed@consilium-comms.com
 Matthew Neal / Olivia Manser

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing, profitable services business
includes an industry leading suite of specialist pharmacovigilance (PV)
solutions, integrated under the PrimeVigilance brand, a full range of
high-quality contract research and trial management services under the Ergomed
brand (CRO), and an internationally recognised specialist expertise in orphan
drug development, under PSR. For further information, visit:
http://ergomedplc.com (http://ergomedplc.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NRAEAEDNASAEEAA